Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance

NCT02673749 is registered in ClinicalTrials.gov with Ritter Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02673749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02673749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance
Lead sponsor
Ritter Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
February 29, 2016
Completion date
October 31, 2016
Enrollment
377 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lactose intolerance